Niagen Bioscience, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $17.4M | $8.6M | $-4.9M | $-16.5M | $-27.1M | $-19.9M | $-32.1M | $-33.3M |
| Depreciation & Amortization | — | — | — | — | — | — | — | $607.0K |
| Depreciation | $612.0K | $663.0K | $870.0K | $869.0K | $890.0K | $871.0K | $762.0K | $607.0K |
| Amortization | $173.0K | $151.0K | $158.0K | $186.0K | $225.0K | $243.0K | $246.0K | $235.0K |
| Stock-Based Compensation | $6.1M | $3.7M | $4.8M | $5.7M | $6.2M | $6.9M | $7.2M | $6.4M |
| Net Cash from Operating Activities | $13.5M | $12.1M | $7.1M | $-15.1M | $-24.2M | $-10.6M | $-20.4M | $-20.9M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | $743.0K | $1.3M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-292.0K | $-143.0K | $-143.0K | $-334.0K | $-409.0K | $-165.0K | $-249.0K | $-1.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $251.0K | $0 | — | — | — | — | — | $404.0K |
| Net Cash from Financing Activities | $6.9M | $5.4M | $-90.0K | $7.7M | $36.1M | $8.7M | $16.9M | $-90.0K |
| Net Change in Cash | $20.1M | $17.3M | $6.9M | $-7.8M | $11.5M | $-2.1M | $-3.8M | $-22.8M |
| Free Cash Flow | — | — | — | — | — | — | $-21.2M | $-22.2M |